TY - JOUR
T1 - Drug-Eluting Stents Versus Bare Metal Stents for Narrowing in Saphenous Vein Grafts
AU - Okabe, Teruo
AU - Lindsay, Joseph
AU - Buch, Ashesh N.
AU - Steinberg, Daniel H.
AU - Roy, Probal
AU - Slottow, Tina L Pinto
AU - Smith, Kimberly
AU - Torguson, Rebecca
AU - Xue, Zhenyi
AU - Satler, Lowell F.
AU - Kent, Kenneth M.
AU - Pichard, Augusto D.
AU - Weissman, Neil J.
AU - Waksman, Ron
PY - 2008/9/1
Y1 - 2008/9/1
N2 - Conflicting data exist regarding an advantage of drug-eluting stents (DES) over bare metal stents (BMS) in catheter-based treatment of saphenous vein graft (SVG) stenoses. This study was undertaken to compare the efficacy of these modalities in that lesion subset. The DES group consisted of 138 cases with 183 lesions (sirolimus-eluting stents, n = 117; paclitaxel-eluting stents, n = 66) and the BMS group consisted of 344 cases with 478 lesions that were followed to 1 year. We examined a composite end point that comprised death, Q-wave myocardial infarction, and target lesion revascularization. More BMS were deployed per patient (p <0.001) and the diameters of BMS deployed was significantly greater (p <0.001). Peak postprocedure values of creatine kinase-MB (p = 0.003) and troponin I (p = 0.05) were higher in BMS. At 1 year there was no significant superiority of DES over BMS with regard to hard end points (death and Q-wave myocardial infarction). In conclusion, this study indicates that both DES and BMS for SVG disease provide acceptably safe and efficacious results, but unlike the case in native coronary arteries, DES use does not reduce the frequency of the need for repeat revascularization.
AB - Conflicting data exist regarding an advantage of drug-eluting stents (DES) over bare metal stents (BMS) in catheter-based treatment of saphenous vein graft (SVG) stenoses. This study was undertaken to compare the efficacy of these modalities in that lesion subset. The DES group consisted of 138 cases with 183 lesions (sirolimus-eluting stents, n = 117; paclitaxel-eluting stents, n = 66) and the BMS group consisted of 344 cases with 478 lesions that were followed to 1 year. We examined a composite end point that comprised death, Q-wave myocardial infarction, and target lesion revascularization. More BMS were deployed per patient (p <0.001) and the diameters of BMS deployed was significantly greater (p <0.001). Peak postprocedure values of creatine kinase-MB (p = 0.003) and troponin I (p = 0.05) were higher in BMS. At 1 year there was no significant superiority of DES over BMS with regard to hard end points (death and Q-wave myocardial infarction). In conclusion, this study indicates that both DES and BMS for SVG disease provide acceptably safe and efficacious results, but unlike the case in native coronary arteries, DES use does not reduce the frequency of the need for repeat revascularization.
UR - http://www.scopus.com/inward/record.url?scp=51749099574&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2008.04.041
DO - 10.1016/j.amjcard.2008.04.041
M3 - Article
C2 - 18721507
AN - SCOPUS:51749099574
VL - 102
SP - 530
EP - 534
JO - The American Journal of Cardiology
JF - The American Journal of Cardiology
SN - 0002-9149
IS - 5
ER -